RHB-102 (BEKINDA®) is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist.
RHB-102 is in development for several gastrointestinal indications:
* Bekinda® is the proposed tradename for RHB-102, which is subject to review by the FDA at the time of NDA filing